Since DCP appears to stimulate the phosphorylated forms of the kinases in the PI3K/Akt/mTOR pathway, we therefore suggest that DCP antagonizes the effects of Sorafenib on HCC through activation of the PI3K/Akt/mTOR signaling pathway. The gene discussed is AKT1; the disease is hepatocellular carcinoma.